Michael Benkowitz sold $3.6M of UTHR
PRESIDENT AND COO at UNITED THERAPEUTICS Corp. 10,000 shares at an average of $364.91, traded Jan 21, 2025, filed Jan 22, 2025.
Score components
- +20RolePresident
- +25Trade size$3.6M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-000456, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | MOption exercise Common Stockindirect: By Trust10b5-1 | +7,500 | $111.00 | $833k | 7,500 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,860 | $362.71 | $675k | 5,640 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,140 | $363.41 | $414k | 4,500 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -800 | $364.84 | $292k | 3,700 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -2,000 | $365.95 | $732k | 1,700 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,199 | $366.68 | $440k | 501 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -401 | $368.08 | $148k | 100 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -100 | $369.19 | $37k | 0 | Jan 22, 2025 |
| Jan 21, 2025 | MOption exercise Common Stockindirect: By Trust10b5-1 | +2,500 | $111.00 | $278k | 2,500 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -900 | $362.88 | $327k | 1,600 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -300 | $364.44 | $109k | 1,300 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -619 | $365.60 | $226k | 681 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -436 | $366.57 | $160k | 245 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -245 | $368.08 | $90k | 0 | Jan 22, 2025 |
| Jan 21, 2025 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -7,500 | $0.00 | $0 | 44,679 | Jan 22, 2025 |
| Jan 21, 2025 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -2,500 | $0.00 | $0 | 17,000 | Jan 22, 2025 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.